Creative Biolabs Launches Artificial T-Cell Stimulator Services

SHIRLEY, NY May 26, 2026 /24-7PressRelease/ — Creative Biolabs, a premier global biotechnology vendor specializing in advanced cell therapy solutions and immunotherapy discovery, has announced the official launch of its comprehensive cell-based artificial T-cell stimulator development services. This strategic expansion aims to provide worldwide researchers with highly robust, reproducible, and scalable tools to streamline the preclinical validation and functional optimization of chimeric antigen receptor (CAR) T-cell therapies.

In vitro T-cell activation and expansion represent critical bottlenecks within modern cell therapy workflows. Traditional chemical or antibody-coated bead-based activation methodologies frequently lack the physiological complexity required to sustain robust, antigen-specific T-cell propagation. To overcome these experimental limitations, cell-based artificial antigen-presenting cells (aAPCs) have emerged as the industry standard for driving precise, targeted immune cell stimulation.

To address diverse research demands, Creative Biolabs has established three dedicated service pipelines tailored to specialized immunological applications:
• Custom cell-based T-cell stimulator development: Engineering stable, custom cell lines that express membrane-bound anti-CD3/anti-CD28 or specific costimulatory ligands to deliver uniform activation signals.
• Antigen-specific CD8+ T-cell stimulator development: Generating tailored cellular platforms that express specific major histocompatibility complex (MHC) Class I molecules loaded with target peptides to evaluate cytotoxic T-lymphocyte (CTL) responses.
• Antigen-specific CD4+ T-cell stimulator development: Creating specialized platforms optimized for MHC Class II molecule presentation to support and sustain helper T-cell activation, profiling, and proliferation.

These advanced cellular platforms provide researchers with highly reproducible systems for rigorous immunogenicity testing, antigen-specific T-cell cloning, and long-term functional evaluation. Platforms expressing specific surface antigens are tailored for CAR-T evaluation, while our MHC-based presentation systems are optimized for TCR-T and tumor-infiltrating lymphocyte (TIL) constructs.. By mimicking a more native, physiological microenvironment in vitro, these engineering services significantly mitigate batch-to-batch variability, reduce early-stage development timelines, and enhance the predictability of translational cell therapy programs.

“Standardizing T-cell stimulation is paramount for generating high-quality preclinical data,” stated a senior scientist at Creative Biolabs. “Our custom cell-based artificial stimulators bridge the gap between artificial in vitro assays and complex in vivo immune responses, giving therapy developers the precise control they need over antigen presentation and costimulatory signaling pathways.”

For complete technical specifications, or to submit an inquiry regarding custom cell line development projects and pricing quotes, please visit https://www.creative-biolabs.com/car-t/.

About Creative Biolabs
Creative Biolabs focuses on advancing next‑generation CAR‑T therapies by supporting every step from scFv discovery to in vitro evaluation. Leveraging its expertise in engineered cell lines, the company provides cell‑based artificial T‑cell stimulator services to enable precise cellular activation and speed the transition of therapeutic candidates from research to clinical development.

—
For the original version of this press release, please visit 24-7PressRelease.com here